{"id":169538,"date":"2026-04-27T16:21:22","date_gmt":"2026-04-27T15:21:22","guid":{"rendered":"https:\/\/m3globalresearch.blog\/?p=169538"},"modified":"2026-04-27T16:21:22","modified_gmt":"2026-04-27T15:21:22","slug":"bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years","status":"publish","type":"post","link":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/","title":{"rendered":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"169538\" class=\"elementor elementor-169538\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5e4f0ee e-flex e-con-boxed e-con e-parent\" data-id=\"5e4f0ee\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-055bdba elementor-widget elementor-widget-text-editor\" data-id=\"055bdba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\tUpdated results from the NEOPRISM-CRC clinical trial show that patients with a specific subtype of bowel cancer who received preoperative immunotherapy have remained cancer-free after almost three years of follow-up, with no relapses recorded among treated participants. The findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and were led by researchers from University College London (UCL) and University College London Hospitals (UCLH).\n<br><br>\nThe trial enrolled 32 patients with stage two or three bowel cancer carrying a mismatch repair-deficient (MMR-d) or microsatellite instability-high (MSI-high) genetic profile, a subgroup representing approximately 10 to 15% of stage two and three bowel cancer cases, or around 2,000 to 3,000 cases per year in the UK. Participants received up to nine weeks of pembrolizumab before surgery, in place of the standard approach of surgery followed by three to six months of chemotherapy.\n<br><br>\nEarlier results had shown that 59% of patients had no detectable signs of disease following treatment and surgery. At 33 months of follow-up, none of the participants had experienced a cancer recurrence, including those who still had residual disease after treatment. By comparison, approximately 25% of patients receiving standard surgery and postoperative chemotherapy are expected to relapse within three years.\n<br><br>\nAlongside survival data, researchers developed personalised blood tests capable of detecting circulating tumour DNA, enabling early assessment of treatment response and disease status. Immune profiling of tumour tissue taken before treatment also showed potential for predicting which patients are most likely to respond, which could inform more tailored treatment decisions in the future.\n<br><br>\nBowel cancer is the fourth most common cancer in the UK, with around 44,000 new cases diagnosed annually.\n<br><br>\nSource: University College London. NEOPRISM-CRC trial results presented at AACR Annual Meeting 2026, April 2026.\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-197f36f e-con-full e-flex e-con e-child\" data-id=\"197f36f\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-62786ed elementor-share-buttons--view-icon elementor-share-buttons--skin-minimal elementor-share-buttons--shape-circle elementor-share-buttons--color-custom elementor-grid-0 elementor-widget elementor-widget-share-buttons\" data-id=\"62786ed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"share-buttons.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-grid\" role=\"list\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\" role=\"listitem\">\n\t\t\t\t\t\t<div class=\"elementor-share-btn elementor-share-btn_email\" role=\"button\" tabindex=\"0\" aria-label=\"Share on email\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-envelope\" viewBox=\"0 0 512 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M502.3 190.8c3.9-3.1 9.7-.2 9.7 4.7V400c0 26.5-21.5 48-48 48H48c-26.5 0-48-21.5-48-48V195.6c0-5 5.7-7.8 9.7-4.7 22.4 17.4 52.1 39.5 154.1 113.6 21.1 15.4 56.7 47.8 92.2 47.6 35.7.3 72-32.8 92.3-47.6 102-74.1 131.6-96.3 154-113.7zM256 320c23.2.4 56.6-29.2 73.4-41.4 132.7-96.3 142.8-104.7 173.4-128.7 5.8-4.5 9.2-11.5 9.2-18.9v-19c0-26.5-21.5-48-48-48H48C21.5 64 0 85.5 0 112v19c0 7.4 3.4 14.3 9.2 18.9 30.6 23.9 40.7 32.4 173.4 128.7 16.8 12.2 50.2 41.8 73.4 41.4z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\" role=\"listitem\">\n\t\t\t\t\t\t<div class=\"elementor-share-btn elementor-share-btn_linkedin\" role=\"button\" tabindex=\"0\" aria-label=\"Share on linkedin\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fab-linkedin\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\" role=\"listitem\">\n\t\t\t\t\t\t<div class=\"elementor-share-btn elementor-share-btn_whatsapp\" role=\"button\" tabindex=\"0\" aria-label=\"Share on whatsapp\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fab-whatsapp\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M380.9 97.1C339 55.1 283.2 32 223.9 32c-122.4 0-222 99.6-222 222 0 39.1 10.2 77.3 29.6 111L0 480l117.7-30.9c32.4 17.7 68.9 27 106.1 27h.1c122.3 0 224.1-99.6 224.1-222 0-59.3-25.2-115-67.1-157zm-157 341.6c-33.2 0-65.7-8.9-94-25.7l-6.7-4-69.8 18.3L72 359.2l-4.4-7c-18.5-29.4-28.2-63.3-28.2-98.2 0-101.7 82.8-184.5 184.6-184.5 49.3 0 95.6 19.2 130.4 54.1 34.8 34.9 56.2 81.2 56.1 130.5 0 101.8-84.9 184.6-186.6 184.6zm101.2-138.2c-5.5-2.8-32.8-16.2-37.9-18-5.1-1.9-8.8-2.8-12.5 2.8-3.7 5.6-14.3 18-17.6 21.8-3.2 3.7-6.5 4.2-12 1.4-32.6-16.3-54-29.1-75.5-66-5.7-9.8 5.7-9.1 16.3-30.3 1.8-3.7.9-6.9-.5-9.7-1.4-2.8-12.5-30.1-17.1-41.2-4.5-10.8-9.1-9.3-12.5-9.5-3.2-.2-6.9-.2-10.6-.2-3.7 0-9.7 1.4-14.8 6.9-5.1 5.6-19.4 19-19.4 46.3 0 27.3 19.9 53.7 22.6 57.4 2.8 3.7 39.1 59.7 94.8 83.8 35.2 15.2 49 16.5 66.6 13.9 10.7-1.6 32.8-13.4 37.4-26.4 4.6-13 4.6-24.1 3.2-26.4-1.3-2.5-5-3.9-10.5-6.6z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\" role=\"listitem\">\n\t\t\t\t\t\t<div class=\"elementor-share-btn elementor-share-btn_facebook\" role=\"button\" tabindex=\"0\" aria-label=\"Share on facebook\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fab-facebook\" viewBox=\"0 0 512 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M504 256C504 119 393 8 256 8S8 119 8 256c0 123.78 90.69 226.38 209.25 245V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.28c-30.8 0-40.41 19.12-40.41 38.73V256h68.78l-11 71.69h-57.78V501C413.31 482.38 504 379.78 504 256z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-grid-item\" role=\"listitem\">\n\t\t\t\t\t\t<div class=\"elementor-share-btn elementor-share-btn_twitter\" role=\"button\" tabindex=\"0\" aria-label=\"Share on twitter\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-share-btn__icon\">\n\t\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fab-twitter\" viewBox=\"0 0 512 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z\"><\/path><\/svg>\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-42ab0c8 e-flex e-con-boxed e-con e-parent\" data-id=\"42ab0c8\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-69c535e elementor-widget elementor-widget-spacer\" data-id=\"69c535e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3216d41 e-con-full e-flex e-con e-child\" data-id=\"3216d41\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5d16fce elementor-widget elementor-widget-heading\" data-id=\"5d16fce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Participate in Paid Oncology Surveys\n<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7863558 elementor-widget elementor-widget-spacer\" data-id=\"7863558\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-39ea63b e-flex e-con-boxed e-con e-parent\" data-id=\"39ea63b\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2540409 e-con-full e-flex e-con e-child\" data-id=\"2540409\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-50213aa e-con-full e-flex e-con e-child\" data-id=\"50213aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3183a7f elementor-align-center elementor-mobile-align-center elementor-widget elementor-widget-button\" data-id=\"3183a7f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm elementor-animation-grow\" href=\"https:\/\/m3globalresearch.blog\/medical-news\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Latest Medical News<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-17270e8 e-con-full e-flex e-con e-child\" data-id=\"17270e8\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;_ha_eqh_enable&quot;:false}\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":1,"featured_media":169595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3200],"tags":[2875],"class_list":["post-169538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-medical-news","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years<\/title>\n<meta name=\"description\" content=\"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years\" \/>\n<meta property=\"og:description\" content=\"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/\" \/>\n<meta property=\"og:site_name\" content=\"M3 Global Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T15:21:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-1024x574.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"574\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"m3gr-blog-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:site\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"m3gr-blog-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/\"},\"author\":{\"name\":\"m3gr-blog-admin\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/11bace963d7a45380011c4911a822a6c\"},\"headline\":\"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years\",\"datePublished\":\"2026-04-27T15:21:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg\",\"keywords\":[\"oncology\"],\"articleSection\":[\"Latest Medical News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/\",\"name\":\"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg\",\"datePublished\":\"2026-04-27T15:21:22+00:00\",\"description\":\"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg\",\"width\":5824,\"height\":3264,\"caption\":\"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"name\":\"M3 Global Research\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\",\"name\":\"M3 Global Research\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":null,\"contentUrl\":null,\"width\":null,\"height\":null,\"caption\":\"M3 Global Research\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/en-gb.facebook.com\\\/M3GlobalResearch\\\/\",\"https:\\\/\\\/x.com\\\/M3GR_Community\",\"https:\\\/\\\/www.instagram.com\\\/m3globalresearch\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/10557915\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/11bace963d7a45380011c4911a822a6c\",\"name\":\"m3gr-blog-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g\",\"caption\":\"m3gr-blog-admin\"},\"sameAs\":[\"https:\\\/\\\/blog.m3globalresearch.com\"],\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/author\\\/m3gr-blog-admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years","description":"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/","og_locale":"en_US","og_type":"article","og_title":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years","og_description":"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.","og_url":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/","og_site_name":"M3 Global Research","article_publisher":"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","article_published_time":"2026-04-27T15:21:22+00:00","og_image":[{"width":1024,"height":574,"url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-1024x574.jpeg","type":"image\/jpeg"}],"author":"m3gr-blog-admin","twitter_card":"summary_large_image","twitter_creator":"@M3GR_Community","twitter_site":"@M3GR_Community","twitter_misc":{"Written by":"m3gr-blog-admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#article","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/"},"author":{"name":"m3gr-blog-admin","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/11bace963d7a45380011c4911a822a6c"},"headline":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years","datePublished":"2026-04-27T15:21:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg","keywords":["oncology"],"articleSection":["Latest Medical News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/","url":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/","name":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#primaryimage"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg","datePublished":"2026-04-27T15:21:22+00:00","description":"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research.","breadcrumb":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#primaryimage","url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg","contentUrl":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg","width":5824,"height":3264,"caption":"Bowel cancer immunotherapy trial shows no relapses, with NEOPRISM-CRC results at the American Association for Cancer Research."},{"@type":"BreadcrumbList","@id":"https:\/\/www.m3globalresearch.com\/blog\/bowel-cancer-immunotherapy-trial-shows-zero-relapses-nearly-three-years\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.m3globalresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Bowel Cancer Immunotherapy Trial Shows Zero Relapses at Nearly Three Years"}]},{"@type":"WebSite","@id":"https:\/\/www.m3globalresearch.com\/blog\/#website","url":"https:\/\/www.m3globalresearch.com\/blog\/","name":"M3 Global Research","description":"","publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m3globalresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization","name":"M3 Global Research","url":"https:\/\/www.m3globalresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/","url":null,"contentUrl":null,"width":null,"height":null,"caption":"M3 Global Research"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","https:\/\/x.com\/M3GR_Community","https:\/\/www.instagram.com\/m3globalresearch","https:\/\/www.linkedin.com\/company\/10557915"]},{"@type":"Person","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/11bace963d7a45380011c4911a822a6c","name":"m3gr-blog-admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb0c444d9d8b383c405133f87af6215220f0327b7f797aec37db4ab6b6b18364?s=96&d=mm&r=g","caption":"m3gr-blog-admin"},"sameAs":["https:\/\/blog.m3globalresearch.com"],"url":"https:\/\/www.m3globalresearch.com\/blog\/author\/m3gr-blog-admin\/"}]}},"jetpack_featured_media_url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/04\/Bowel-Cancer-Immunotherapy-Trial-scaled.jpeg","jetpack_sharing_enabled":true,"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/169538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=169538"}],"version-history":[{"count":0,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/169538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media\/169595"}],"wp:attachment":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=169538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=169538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=169538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}